GIP and GLP-1 receptor co-agonist
CT-388 2.0 mg injection
CT388_SC_2p0MG_OTHER
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.45 (0.01 to 15.52) | 0.65 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.23 (0.00 to 4.71) | 0.91 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.29 (0.00 to 6.84) | 0.90 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.48 (0.09 to 16.09) | 0.56 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.44 (0.09 to 17.14) | 0.57 |